Atrium Therapeutics, Inc. (RNA) NASDAQ
13.44
-0.03(-0.22%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
13.44
-0.03(-0.22%)
Currency In USD
Address
10578 Science Center Drive
San Diego, CA 92121
United States of America (the)
Phone
619 876 0700
Sector
Healthcare
Industry
Biotechnology
Employees
N/A
First IPO Date
February 27, 2026
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.